Copenhagen uPAR prostate cancer (CuPCa) database: protocol and early results.
Biomark Med
; 10(2): 209-16, 2016.
Article
en En
| MEDLINE
| ID: mdl-26764285
ABSTRACT
AIM:
Urokinase plasminogen activator receptor (uPAR) plays a central role during cancer invasion by facilitating pericellular proteolysis. We initiated the prospective 'Copenhagen uPAR Prostate Cancer' study to investigate the significance of uPAR levels in prostate cancer (PCa) patients.METHODS:
Plasma samples and clinical data from patients with newly diagnosed PCa have been collected prospectively. The uPAR forms have been measured in plasma using time-resolved fluorescence immunoassays.RESULTS:
The level of intact uPAR(I-III) did not differ. Plasma uPAR(I-III) + uPAR(II-III) levels and uPAR(I) levels were significantly higher in hormone-naive and castrate-resistant patients compared with patients with localized disease (both p < 0.0001).CONCLUSION:
Our results show that cleaved uPAR forms are significantly increased in patients with advanced PCa.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Biomarcadores de Tumor
/
Receptores del Activador de Plasminógeno Tipo Uroquinasa
/
Neoplasias de la Próstata Resistentes a la Castración
Tipo de estudio:
Evaluation_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Aged
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
Europa
Idioma:
En
Revista:
Biomark Med
Asunto de la revista:
BIOQUIMICA
/
MEDICINA
Año:
2016
Tipo del documento:
Article
País de afiliación:
Dinamarca
Pais de publicación:
ENGLAND
/
ESCOCIA
/
GB
/
GREAT BRITAIN
/
INGLATERRA
/
REINO UNIDO
/
SCOTLAND
/
UK
/
UNITED KINGDOM